Waail Rozi

Waail Rozi

Auto-generated profile, based on publicly available information

Waail Rozi

Internal Medicine, Hamad Medical Corporation, Doha, QAT

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
WRWaail Mohammed Rozi
Waail Mohammed Rozi
ARAlaa Rahhal
Alaa Rahhal
EAElrazi Ali
Elrazi Ali
AAAbdulrahman Fadhl Al-Mashdali
Abdulrahman Fadhl Al-Mashdali
YHYousef Hilan
Yousef Hilan
MYMohamed Yassin
Mohamed Yassin
Waail Mohammed Rozi, Alaa Rahhal, Elrazi A Ali, Abdulrahman Fadhl Al-Mashdali, Yousef Hilan, Ibrahim Khamees, Liam J Fernyhough, Mohamed A Yassin; Direct Oral A

5 January 2023 in Cureus
Verified
Journal Article
Open access
MAMohammad Abu-Tineh
Mohammad Abu-Tineh
EAElrazi Ali
Elrazi Ali
AAAwni Alshurafa
Awni Alshurafa
Abdulqadir J. NashwanAbdulqadir J. Nashwan
Abdulqadir J. Nashwan
KAKhalid Albsheer
Khalid Albsheer
MYMohamed Yassin
Mohamed Yassin
Introduction: Multiple studies have demonstrated that tyrosine kinase inhibitors (TKIs) exert a significant extent of control over chronic myeloid leukemia (CML), as evidenced by studies such as the population-based Swedish CML registry, which found that patients reaching age 70 had a relative survival rate close to one when compared to the general population. Consequently, new perspectives on the safety of treatments have emerged, particularly in the context of their impact on fatherhood in men. According to the authors, this is the first study to examine the effect of TKIs on fatherhood in CML patients. Methods: A single-center, mixed-design study (retrospective data review and phone interviews) was conducted with CML male patients in the chronic or accelerated phase, evaluating the effect of imatinib, dasatinib, and nilotinib on their fatherhood, irrespective of whether they were administered as a first, second, or third line of treatment. Results: The study included interviews with 150 patients. Included were 27 patients. The average age was approximately 44.5 years. One hundred percent of the patients were in the chronic phase. The median age at first conception following TKI therapy was 36, and the median duration of TKI therapy was approximately seven years. The total number of offspring was 49; 98% were born at term and had a normal birth weight. No reports of stillbirths, fetal deaths, or congenital malformations were made. All the offspring grew and developed normally. No CML-related cancers were reported in any of the newborns. Conclusion: Around 98% of male CML patients receiving imatinib, dasatinib, or nilotinib did not experience a negative impact on their fatherhood or the health of their children. However, improved education for patients beginning treatment with TKIs addresses the potential psychological worry of having an unfavorable effect on their fertility or offspring, which may increase medication adherence.

6 December 2021 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
EAElrazi Ali
Elrazi Ali
QAQusai Al-Maharmeh
Qusai Al-Maharmeh
WRWaail Mohammed Rozi
Waail Mohammed Rozi
MHMhd Baraa Habib
Mhd Baraa Habib
AAAhmed Abdallah
Ahmed Abdallah
MYMohamed Yassin
Mohamed Yassin
Introduction and importance Coronavirus disease 2019 (COVID-19) is a recently discovered disease that has yet to be thoroughly described. It is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel virus that can be transmitted easily from human to human, mainly by the respiratory route. The disease often presents with non-specific symptoms such as fever, headache, and fatigue, accompanied by respiratory symptoms (e.g., cough and dyspnea) and other systemic involvement. Currently, vaccination is the primary strategy to prevent transmission and reduce disease severity. However, vaccines have side effects, and the consequences of vaccination in different diseases are not well established. Moreover, the impact of SARS-CoV-2 vaccination during pregnancy is another not well-known area. Case presentation: We present a young lady known to have ITP, which was controlled for years, presented with relapse after taking the SARS-CoV-2 vaccine during pregnancy. Clinical discussion The patient had a relapse of ITP after the introduction of the first dose of the COVID-19 vaccine, which worsened further after the second dose. This suggests that patients with ITP who develop flare post-SARS-CoV-2 vaccine should have their second dose delayed, particularly if pregnant. Conclusion: To avoid further deterioration in platelet count, and avoid confusion due to the presence of different causes of thrombocytopenia and avoid complications related to thrombocytopenia during pregnancy which can affect the mode of delivery. The case is reported in line with the scare 2020 criteria Agha RA, Franchi T, Sohrabi C, Mathew G, for the SCARE Group. The SCARE 2020 Guideline: Updating Consensus Surgical CAse REport (SCARE) Guidelines, International Journal of Surgery 2020; 84:226–230.

25 January 2021
Verified
Preprint
Open access
PDF file
IKIbrahim Khamees
Ibrahim Khamees
MYMohamed Yassin
Mohamed Yassin
WRWaail Rozi
Waail Rozi
Hemoglobin S (HBS) and hemoglobin E (HBE) are common hemoglobinopathies, but combined heterozygosity of HBS and HBE (HBSE) is relatively a rare disease. Most reports suggest that HBSE is generally benign condition. In this report we describe a 17-year-old male patient presenting with acute chest syndrome treated with exchange transfusion.

23 December 2021 in Medicine
Verified
Journal Article
Open access
WRWaail Rozi
Waail Rozi
EAElrazi Awadelkarim Hamid Ali
Elrazi Awadelkarim Hamid Ali
AAAbdulrahman F. Al-Mashdali
Abdulrahman F. Al-Mashdali
MAMohamed Abdelrazek
Mohamed Abdelrazek
MYMohamed Yassin
Mohamed Yassin
Introduction: Sickle cell disease (SCD) is a hematological disorder characterized by sickling of red blood cells. Patients are at increased risk of venous thromboembolism. There are no guidelines for the management of venous thromboembolism in sickle cell disease specifically in terms of the anticoagulant of choice. Patient concerns: Here, we report a case of a 30-year-old lady with past medical history of sickle cell disease who came with chest pain and shortness of breath. Diagnosis: We found that she has bilateral pulmonary embolism (PE). Intervention: She was started on rivaroxaban. Outcome: The patient was followed for 18 months, she did not suffer from recurrence of PE, and she did not develop any complications related to rivaroxaban. Conclusion: We concluded that rivaroxaban is effective in treating PE in sicklers and also it is safe.

30 November 2022 in Cureus
Verified
Journal Article
Open access
IKIbrahim Khamees
Ibrahim Khamees
EAElrazi A Ali
Elrazi A Ali
LMLujain Malkawi
Lujain Malkawi
WRWaail Rozi
Waail Rozi
MYMohamed Yassin
Mohamed Yassin
The Coronavirus disease 2019 (COVID-19) is considered the largest pandemic in modern history. Since the first case was reported in 2019, several mutations have affected the severe acute respiratory syndrome-Coronavirus-2 (SARS-CoV-2), resulting in the emergence of new strains. These strains vary significantly in severity and transmissibility. The Omicron (B.1.1.529) variant was reported to cause mild disease in those affected, but little is known about the effect of Omicron on patients with chronic lymphocytic leukemia (CLL). We are reporting a case series of three patients with CLL who experienced infection with the SARS-CoV-2 Omicron variant and their outcomes.